Dissolution testing of oral modified-release dosage forms

Authors

  • Grzegorz Garbacz,

    1. Institute of Pharmacy, Ernst Moritz Arndt University, Greifswald, Germany
    Search for more papers by this author
  • Sandra Klein

    Corresponding author
    1. Institute of Pharmacy, Ernst Moritz Arndt University, Greifswald, Germany
      Sandra Klein, Institute of Pharmacy, University of Greifswald, Felix Hausdorff Street 3, Greifswald 17489, Germany. E-mail: sandra.klein@uni-greifswald.de
    Search for more papers by this author

Sandra Klein, Institute of Pharmacy, University of Greifswald, Felix Hausdorff Street 3, Greifswald 17489, Germany. E-mail: sandra.klein@uni-greifswald.de

Abstract

Objectives  The in-vivo performance of oral modified-release dosage forms is determined by the interplay of various physiological- and dosage-form-derived parameters. Thus it is often a challenge to predict the in-vivo drug-release behaviour from modified-release dosage forms based solely on in-vitro release rates.

Key findings  For a long time the most common procedure to obtain in-vitro/in-vivo correlations for modified-release formulations was to apply test conditions typically used for quality control on a retrospective basis. Such so-called ‘compendial approaches’ are typically not biorelevant with respect to volumes, composition and physicochemical properties of the test media and also do not take into consideration the mechanical and hydrodynamic forces that may influence dosage-form behaviour during passage through the gastrointestinal tract.

Summary  This review provides an overview of physiological conditions relevant to in-vivo drug release and of dissolution models which, based on current scientific findings on human gastrointestinal physiology, have been developed to enable a better prediction of the in-vivo performance of oral MR dosage forms.

Ancillary